InvestorsContact Us
    Lead Program

    Ambrilux™
    Dental Gel

    Piezoelectric Regeneration for Periodontal Bone Loss

    Preclinical | First-in-Human planned 2026
    The Challenge

    Why Periodontal Bone Loss

    Periodontal disease is the most prevalent untreated regenerative condition in medicine. Once bone is lost, there is no predictable, non-surgical way to restore it.

    Ambrilux™ Dental Gel was engineered to change that.

    >1BPeople affected globally
    12%U.S. adults over 30 impacted
    #1Cause of adult tooth loss
    Beyond the Mouth

    Periodontal Disease is a Systemic Problem

    Oral bacteria and chronic inflammation don't stay in the mouth.
    They enter the bloodstream and affect organs throughout the body.

    Neurological

    Cognitive decline

    Bacteria cross the blood-brain barrier, contributing to neuroinflammation and increased Alzheimer's risk.

    ↓Scroll to explore

    Mechanism

    How Ambrilux Works

    Ambrilux leverages Oral Biolife's piezoelectric regenerative platform, tuned specifically for the periodontal environment.

    01

    Place

    Ambrilux is delivered as an injectable, light-curable scaffold that conforms to periodontal bone defects.

    02

    Activate

    Everyday micromotion—chewing, speaking, normal oral function—generates localized bioelectrical signaling.

    03

    Regenerate

    These signals activate physiological osteogenesis as the scaffold biodegrades, guiding organized new bone formation.

    No external energy. No drugs. No biologics.

    Only endogenous mechanical energy, precisely directed.

    Results

    Validation and Safety

    We have demonstrated 100% bone regeneration in pre-clinical canine ligature models. Multi-species studies confirm piezoelectric mechanotransduction.

    The platform exhibits a clean safety profile, consistent with decades of clinical use of electro-mechanical stimulation in bone healing.

    Piezoelectric bone regeneration validation
    Pathway

    Clinical Translation

    Ambrilux is designed for clinical translation with a clear regulatory pathway.

    Mechanical mechanism of action (non-pharmacologic)
    No systemic exposure
    No growth factors or biologics
    Clean animal-to-human translation rationale

    The program is aligned with a De Novo regulatory pathway, supported by robust preclinical data.

    Vision

    Looking Ahead

    Ambrilux is the first clinical translation of piezoelectric regeneration in humans. By restoring periodontal bone without surgery, it establishes the foundation for a new category of mechanically driven regenerative medicine.

    Interested in Ambrilux?

    Contact us to learn more about partnership and investment opportunities.

    Get in Touch